Login to Your Account

Approved in Europe, under review in U.S.

LONDON – Astrazeneca plc can finally look forward to a return on its $2.7 billion purchase of Lokelma, after the orally administered hyperkalemia treatment broke through a series of regulatory setbacks to win approval in Europe.

more »

Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.



Partners in Focus